Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:51 UTC |
---|
Update Date | 2022-03-07 02:51:54 UTC |
---|
HMDB ID | HMDB0015247 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Nifedipine |
---|
Description | Nifedipine, also known as procardia or adalat, belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. Dihydropyridinecarboxylic acids and derivatives are compounds containing a dihydropyridine moiety bearing a carboxylic acid group. Nifedipine is a drug which is used for the management of vasospastic angina, chronic stable angina, hypertension, and raynaud's phenomenon. may be used as a first line agent for left ventricular hypertrophy and isolated systolic hypertension (long-acting agents). . Nifedipine is a very strong basic compound (based on its pKa). In humans, nifedipine is involved in tamoxifen action pathway. The vasodilatory effects of nifedipine result in an overall decrease in blood pressure. By blocking the calcium channels, Nifedipine inhibits the spasm of the coronary artery and dilates the systemic arteries, results in a increase of myocardial oxygen supply and a decrease in systemic blood pressure. Calcium ions entering the cell through these channels bind to calmodulin. By inhibiting the influx of calcium in smooth muscle cells, nifedipine prevents calcium-dependent myocyte contraction and vasoconstriction. Nifedipine is used to treat hypertension and chronic stable angina. |
---|
Structure | COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3 |
---|
Synonyms | Value | Source |
---|
4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsaeuredimethylester | ChEBI | Adalat | ChEBI | Adapine | ChEBI | Coracten | ChEBI | Nifecard | ChEBI | Nifecor | ChEBI | Nifedipino | ChEBI | Nifedipinum | ChEBI | Nifedipres | ChEBI | Procardia | ChEBI | Afeditab CR | Kegg | BAY-a-1040 | HMDB | Cordipin | HMDB | Monohydrochloride, nifedipine | HMDB | Nifedipine monohydrochloride | HMDB | Nifedipine orion brand | HMDB | Nifedipine pfizer brand | HMDB | Nifedipine-gtis | HMDB | AWD pharma brand OF nifedipine | HMDB | BAY a 1040 | HMDB | Bayer brand OF nifedipine | HMDB | Korinfar | HMDB | Nifedipine krka brand | HMDB | Pfizer brand OF nifedipine | HMDB | Procardia XL | HMDB | Cordipine | HMDB | Fenigidin | HMDB | Orion brand OF nifedipine | HMDB | Adcock ingram brand OF nifedipine | HMDB | Corinfar | HMDB | KRKA brand OF nifedipine | HMDB | Nifangin | HMDB | Nifedipine bayer brand | HMDB | Nifedipine gtis | HMDB | Vascard | HMDB |
|
---|
Chemical Formula | C17H18N2O6 |
---|
Average Molecular Weight | 346.3346 |
---|
Monoisotopic Molecular Weight | 346.116486318 |
---|
IUPAC Name | 3,5-dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
---|
Traditional Name | nifedipine |
---|
CAS Registry Number | 21829-25-4 |
---|
SMILES | COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC |
---|
InChI Identifier | InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3 |
---|
InChI Key | HYIMSNHJOBLJNT-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. Dihydropyridinecarboxylic acids and derivatives are compounds containing a dihydropyridine moiety bearing a carboxylic acid group. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Pyridines and derivatives |
---|
Sub Class | Hydropyridines |
---|
Direct Parent | Dihydropyridinecarboxylic acids and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Dihydropyridinecarboxylic acid derivative
- Nitrobenzene
- Nitroaromatic compound
- Monocyclic benzene moiety
- Dicarboxylic acid or derivatives
- Benzenoid
- Methyl ester
- Enoate ester
- Alpha,beta-unsaturated carboxylic ester
- Vinylogous amide
- Organic nitro compound
- Carboxylic acid ester
- C-nitro compound
- Amino acid or derivatives
- Azacycle
- Propargyl-type 1,3-dipolar organic compound
- Organic 1,3-dipolar compound
- Carboxylic acid derivative
- Allyl-type 1,3-dipolar organic compound
- Secondary aliphatic amine
- Enamine
- Organic oxoazanium
- Secondary amine
- Organopnictogen compound
- Carbonyl group
- Hydrocarbon derivative
- Organic oxide
- Organic nitrogen compound
- Organonitrogen compound
- Organooxygen compound
- Organic oxygen compound
- Amine
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Not Available | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 172 - 174 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.018 g/L | Not Available | LogP | 2 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Nifedipine,1TMS,isomer #1 | COC(=O)C1=C(C)N([Si](C)(C)C)C(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+](=O)[O-] | 2510.8 | Semi standard non polar | 33892256 | Nifedipine,1TMS,isomer #1 | COC(=O)C1=C(C)N([Si](C)(C)C)C(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+](=O)[O-] | 2304.5 | Standard non polar | 33892256 | Nifedipine,1TMS,isomer #1 | COC(=O)C1=C(C)N([Si](C)(C)C)C(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+](=O)[O-] | 3515.0 | Standard polar | 33892256 | Nifedipine,1TBDMS,isomer #1 | COC(=O)C1=C(C)N([Si](C)(C)C(C)(C)C)C(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+](=O)[O-] | 2739.4 | Semi standard non polar | 33892256 | Nifedipine,1TBDMS,isomer #1 | COC(=O)C1=C(C)N([Si](C)(C)C(C)(C)C)C(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+](=O)[O-] | 2547.7 | Standard non polar | 33892256 | Nifedipine,1TBDMS,isomer #1 | COC(=O)C1=C(C)N([Si](C)(C)C(C)(C)C)C(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+](=O)[O-] | 3518.2 | Standard polar | 33892256 |
|
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Nifedipine GC-MS (Non-derivatized) - 70eV, Positive | splash10-00n0-1195000000-7e4e6770da078dff666a | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Nifedipine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Nifedipine LC-ESI-qTof , Positive-QTOF | splash10-0v4i-1691000000-c4842fe2c3070d6e90dd | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nifedipine , positive-QTOF | splash10-0v4i-1691000000-c4842fe2c3070d6e90dd | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nifedipine 40V, Positive-QTOF | splash10-0fxy-0940000000-23744bb64d78de13acb0 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nifedipine 20V, Positive-QTOF | splash10-0udi-0490000000-93e13f20c2b96fd21829 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nifedipine 10V, Positive-QTOF | splash10-0gia-0192000000-7d81ad696e86cf9c1ebd | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nifedipine 35V, Positive-QTOF | splash10-0uy0-0492000000-a75cb00c5cb3e8f0c2c8 | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nifedipine 10V, Positive-QTOF | splash10-0002-0009000000-9dada371e9f135db7acf | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nifedipine 20V, Positive-QTOF | splash10-0002-0009000000-568982a20ecb8f9fbb78 | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nifedipine 40V, Positive-QTOF | splash10-0095-5196000000-a8be024a63e01b939a2a | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nifedipine 10V, Negative-QTOF | splash10-0002-0009000000-2d2fce579fb1386f8738 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nifedipine 20V, Negative-QTOF | splash10-0002-0009000000-5ebd1372ca17a57d813a | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nifedipine 40V, Negative-QTOF | splash10-0005-3095000000-ad731a5dda860a940c77 | 2016-08-03 | Wishart Lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | |
---|
Biospecimen Locations | |
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB01115 | | details | Urine | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB01115 | | details |
|
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | DB01115 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 4330 |
---|
KEGG Compound ID | C07266 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Nifedipine |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 4485 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 7565 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | HNIFEDIPINE |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Download (PDF) |
---|
General References | - Grossman E, Messerli FH, Grodzicki T, Kowey P: Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA. 1996 Oct 23-30;276(16):1328-31. [PubMed:8861992 ]
- Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000 Jul 29;356(9227):366-72. [PubMed:10972368 ]
- Varon J, Marik PE: Clinical review: the management of hypertensive crises. Crit Care. 2003 Oct;7(5):374-84. Epub 2003 Jul 16. [PubMed:12974970 ]
- Odou P, Ferrari N, Barthelemy C, Brique S, Lhermitte M, Vincent A, Libersa C, Robert H: Grapefruit juice-nifedipine interaction: possible involvement of several mechanisms. J Clin Pharm Ther. 2005 Apr;30(2):153-8. [PubMed:15811168 ]
- Poole-Wilson PA, Kirwan BA, Voko Z, de Brouwer S, van Dalen FJ, Lubsen J: Safety of nifedipine GITS in stable angina: the ACTION trial. Cardiovasc Drugs Ther. 2006 Feb;20(1):45-54. [PubMed:16552473 ]
- Takahashi D, Oyunzul L, Onoue S, Ito Y, Uchida S, Simsek R, Gunduz MG, Safak C, Yamada S: Structure-activity relationships of receptor binding of 1,4-dihydropyridine derivatives. Biol Pharm Bull. 2008 Mar;31(3):473-9. [PubMed:18310913 ]
|
---|